Get the Stockscreener App
2.79
1.09%
0.03
Pre-market:
2.80
0.010
+0.36%
Xenetic Biosciences Inc stock is traded at $2.79, with a volume of 7,989.
It is up +1.09% in the last 24 hours and down -29.90% over the past month.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.
See More
Previous Close:
$2.76
Open:
$2.76
24h Volume:
7,989
Relative Volume:
0.11
Market Cap:
$4.30M
Revenue:
$2.54M
Net Income/Loss:
$-4.13M
P/E Ratio:
-1.0145
EPS:
-2.75
Net Cash Flow:
$-4.11M
1W Performance:
-11.85%
1M Performance:
-29.90%
6M Performance:
-32.28%
1Y Performance:
-14.68%
1-Day Range:
$2.625
$2.79
1-Week Range:
$2.625
$3.15
52-Week Range:
$2.20
$5.2683
Xenetic Biosciences Inc Stock (XBIO) Company Profile
Name
Xenetic Biosciences Inc
Sector
Industry
Phone
781-778-7720
Address
945 CONCORD ST., FRAMINGHAM, MA
Compare XBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XBIO
Xenetic Biosciences Inc
|
2.79 | 4.26M | 2.54M | -4.13M | -4.11M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-20 | Initiated | Maxim Group | Buy |
Xenetic Biosciences Inc Stock (XBIO) Latest News
Xenetic Biosciences Reports Improved Financial Performance - TipRanks
Xenetic Biosciences 2025 Q2 Earnings Improved Losses but Revenue Declines - AInvest
Using flow based indicators on Xenetic Biosciences Inc.Historical Market Behavior and Trend Summary - Newser
Xenetic Biosciences: Can DNase-Based Therapies Justify the Valuation Amid Financial Losses? - AInvest
Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates - Nasdaq
Xenetic Biosciences: Q2 Earnings Snapshot - San Francisco Chronicle
Xenetic Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Xenetic Biosciences, Inc. SEC 10-Q Report - TradingView
Does Xenetic Biosciences Inc. meet Warren Buffett’s criteriaHigh Return in Low Timeframe - newsyoung.net
Should you hold or exit Xenetic Biosciences Inc. nowEquity Portfolio Outlook and Performance Summary - Newser
Why Xenetic Biosciences Inc. stock attracts strong analyst attentionFree Sector Rotation Based Trading Opportunities - Newser
Has Xenetic Biosciences Inc. found a price floorFree Buy Alerts With Low Risk Confirmation - Newser
Is Xenetic Biosciences Inc. stock entering bullish territoryReal-Time Investment Picks with Accuracy - Newser
Xenetic Biosciences Inc. stock trend forecastFree Price Action Based Buy Opportunity List - Newser
Xenetic Biosciences Inc. stock retracement – recovery analysisShort-Term Upside Breakout Forecast System - Newser
Xenetic Biosciences (XBIO) to Release Earnings on Tuesday - Defense World
Xenetic Biosciences XBIO 2025Q2 Earnings Preview Upside Potential Driven by Strategic Partnerships - AInvest
Top chart patterns to watch in Xenetic Biosciences Inc.Buy/Sell Zone Confirmation Technical Analysis - Newser
Will Xenetic Biosciences Inc. benefit from macro trendsEarly Buy Opportunity with Chart Triggers - Newser
Xenetic Biosciences Inc expected to post a loss of 64 cents a shareEarnings Preview - TradingView
Is Xenetic Biosciences Inc. meeting your algorithmic filter criteriaDaily Pick Forecast with Entry Zones - Newser
What makes Xenetic Biosciences Inc. stock price move sharplyEarly Entry Planner for Swing Candidates - Newser
Xenetic Biosciences Inc. stock outlook for YEARDaily Market Momentum Summary and Strategy - Newser
Xenetic Biosciences, Inc. (NASDAQ:XBIO) Short Interest Up 69.9% in July - Defense World
How Xenetic Biosciences Inc. stock performs during market volatilityFree Entry Plan for Oversold Reversal Stocks - Newser
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma - The Columbus Dispatch
Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform - Lancaster Eagle-Gazette
What machine learning models say about Xenetic Biosciences Inc.AI Volatility Forecast and Risk Monitor - Newser
Buy Signal for Xenetic Biosciences Inc. Stock Key Technical Indicators to WatchAI Model Forecasting Reversal and Breakout Zones - Newser
What drives Xenetic Biosciences Inc. stock priceReal-time trading signals for maximum returns - Jammu Links News
When is Xenetic Biosciences Inc. stock expected to show significant growthMaximize returns with expert trading insights - Jammu Links News
What are the technical indicators suggesting about Xenetic Biosciences Inc.Get alerts on top growth stocks daily - Jammu Links News
Should I hold or sell Xenetic Biosciences Inc. stock in 2025Free Technical Analysis Support - Jammu Links News
Is Xenetic Biosciences Inc. a good long term investmentTriple returns potential - Jammu Links News
What catalysts could drive Xenetic Biosciences Inc. stock higher in 2025Stay ahead with daily expert stock picks - Jammu Links News
Is Xenetic Biosciences Inc. stock overvalued or undervaluedAchieve breakthrough profits with expert advice - Jammu Links News
What are analysts’ price targets for Xenetic Biosciences Inc. in the next 12 monthsUnlock powerful trading signals for profits - Jammu Links News
Does Xenetic Biosciences Inc. stock perform well during market downturnsInvest smarter with expert trading signals - Jammu Links News
What are Xenetic Biosciences Inc. company’s key revenue driversAchieve rapid portfolio appreciation today - Jammu Links News
Xenetic Biosciences Inc Stock (XBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.91%
3.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):